Frontlight ResearchEarly access
CompletedNo phase
Evaluation of DiaSorin LIAISON® PTX3 (Long Pentraxin 3) Assay in Patients With Pneumonia
Key facts
- Who runs it
- Diasorin Italia S.p.A.
- Where
- Italy2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 281 people enrolled
- Started
- 20 Sept 2021
- Ended
- 29 Mar 2024
- Type of study
- Observational
- Treatments tested
- PTX3 assay
- Record updated
- 8 July 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Subjects willing and able to sign the approved Informed Consent form in accordance with international and national regulations
- Patients diagnosed with pneumonia, either CAP, HAP, VAP
- Collection of plasma samples within 24 hours from pneumonia diagnosis (for CAP diagnosis is usually made at ED presentation and for HAP and VAP diagnosis is made during hospital stay)
- K2 EDTA plasma samples dedicated to the study have a minimum volume of 3 mL
Who cannot take part
- Patients who are currently pregnant
- Samples collected and/or stored in an inappropriate way
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
LIAISON® PTX3 is an in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of Long Pentraxin 3 (PTX3) in human plasma samples.
Read full original descriptionShow less
LIAISON® PTX3, in conjunction with clinical evaluation and other laboratory findings, may serve as an aid in the determination of disease severity and prognosis of patients with community-acquired (CAP) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).
Treatments tested
- PTX3 assay
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- A machine learning model including pentraxin-3 as predictor of outcomes in community-acquired pneumonia.Journal of translational medicine, 2025
- Record updated
- 8 July 2024